Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

ConditionPrimary Membranous Nephropathy

Trial statusRecruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age18-75

SponsorVertex Pharmaceuticals Incorporated

About this trial

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Povetacicept
Tacrolimus

Treatment groups

176 Participants

are divided into 3 treatment groups

Locations

102

Australia

Monash Medical Centre Clayton Australia

Concord Repatriation General Hospital Concord Australia

St George Private Hospital Kogarah Australia

University of Newcastle - John Hunter Hospital (JHH) New Lambton Heights Australia

Sponsors and collaborators

Vertex Pharmaceuticals Incorporated

Lead sponsor

Zai Lab (Shanghai) Co., Ltd. (for China only)

Collaborator

Source ClinicalTrials.gov